News | April 22, 2026
Astellas & Pfizer win FDA priority review for bladder cancer treatment expansion
A decision is expected by August 17, 2026 under the Prescription Drug User Fee Act timeline
A decision is expected by August 17, 2026 under the Prescription Drug User Fee Act timeline
Together, the companies aim to deliver an integrated toolkit for biomarker discovery and clinical research
The newly formed team is led by Tomabu Adjobimey, an immunologist known for his work in host-pathogen interactions and immune modulation
SBE303 targets Nectin-4, an adhesion protein overexpressed in multiple tumor types, including urothelial, lung, and breast cancers
Experts highlighted how robotic-assisted procedures are improving surgical precision, reducing complications, and enabling faster recovery
Move to accelerate cancer care expansion across India
The investment will support the company’s plans to expand its network of specialised surgical hospitals across India.
At the core of Verida is Spectral Precise Image technology paired with a third-generation Nano-panel Precise dual-layer detector and an AI-based deep learning reconstruction engine
Revvity is positioning its technologies as a connected engine for discovery
The upcoming multi-center, multinational Phase 1 study will evaluate safety, tolerability, pharmacokinetics, and early signs of efficacy
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
